- \n
- Updated data from the Phase 1\/2 RAINFOL\u2122-01 trial showed rinatabart sesutecan (Rina-S\u00ae<\/sup>) 100 mg\/m2<\/sup> demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FR\u03b1 expression<\/strong><\/li>\n
- A Phase 3 trial in endometrial cancer is underway<\/strong><\/li>\n
- U.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer<\/strong><\/li>\n<\/ul>\n
COPENHAGEN, Denmark–(BUSINESS WIRE<\/a>)–Genmab A\/S<\/b><\/a> (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1\/2 RAINFOL\u2122-01 trial evaluating rinatabart sesutecan (Rina-S\u00ae<\/sup>)<\/strong><\/b>, an investigational folate receptor alpha (FR\u03b1)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg\/m\u00b2 every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. Additionally, at a median study follow-up of one year, 63.6% of responders (including CRs) in the 100 mg\/m\u00b2 cohort maintained their responses and remain on treatment. The responses were observed regardless of FR\u03b1 expression levels. The updated results were presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.<\/p>\n
\nContinued evaluation of single-agent Rina-S 100 mg\/m2<\/sup> in patients with advanced EC is ongoing in the Phase 2 RAINFOL-01 trial (NCT05579366<\/a>) and thePhase 3 RAINFOL-03 trial (NCT07166094<\/a>).<\/p>\n
\n\u201cWomen with advanced endometrial cancer are often facing a difficult path, while doctors are confronted with not having enough treatment options,\u201d said Noelle Cloven, M.D., Texas Oncology Fort Worth, Sarah Cannon Research Institute, and study investigator. \u201cThat\u2019s why these data signals with Rina-S in the updated Phase 1\/2 RAINFOL-01 data are encouraging \u2013 they point to the possibility of providing more choices for patients in the future.\u201d<\/p>\n
\nThe B2 cohort of the Phase 1\/2 RAINFOL-01 study (NCT05579366<\/a>) is a dose expansion cohort evaluating the efficacy and safety of Rina-S in patients with advanced or recurrent endometrial cancer. In the study, 64 patients with heavily pretreated advanced or recurrent endometrial cancer whose disease had progressed on or after an anti-PD-(L)1 and platinum-based chemotherapy were enrolled and treated with Rina-S. Patients were administered either 100 mg\/m2<\/sup> (n=22) (selected dose for Phase 3 clinical trial) or 120 mg\/m2<\/sup> (n=42) of Rina-S. In the 100 mg\/m2<\/sup> cohort, the confirmed ORR was 50.0%, including two CRs. Anti-tumor activity was also observed in patients treated with Rina-S 120 mg\/m2<\/sup> Q3W, which resulted in 44.1% confirmed ORR and one CR. Study participants were previously treated with a median of three lines of therapy (range 1-8). Earlier results from this cohort were previously presented<\/a> at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n
\nCommon treatment emergent adverse events (TEAEs; all grades) consisted primarily of cytopenias and low-grade gastrointestinal (GI) events. To date, there have been no signals of ocular toxicities, neuropathy, or interstitial lung disease (ILD) observed in Rina-S clinical trials consistent with prior reports.Serious TEAEs (Grade 3 or higher), occurred in 36.4% and 52.4% of patients treated with Rina-S 100 mg\/m2<\/sup> and 120 mg\/m2<\/sup>, respectively. Hematologic adverse events did not require significant dose reduction and were associated with low rates of treatment discontinuation.<\/p>\n
\n\u201cWith this updated data, we are seeing additional momentum behind the possibilities of Rina-S,\u201d said Tahi Ahmadi, M.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines at Genmab. \u201cAs a wholly owned, novel antibody-drug conjugate, Rina-S reflects Genmab\u2019s vision to accelerate our innovative, late-stage pipeline that has the potential to redefine possibilities for patients with certain gynecologic cancers.\u201d<\/p>\n
\nRina-S is advancing through late-stage development supported by a growing portfolio of clinical trials, including the ongoing Phase 1\/2 RAINFOL-01 trial (NCT05579366<\/a>), the Phase 3 RAINFOL-03 trial (NCT07166094<\/a>) in patients with endometrial cancer now underway and the Phase 3 RAINFOL-02 trial (NCT06619236<\/a>) in patients with platinum resistant ovarian cancer (PROC). The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy Designation (BTD) to Rina-S for the treatment of adult patients with recurrent or progressive EC who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.<\/p>\n
About the RAINFOLTM <\/sup>-01 Trial
\n
<\/b>RAINFOL\u2122-01 (NCT05579366<\/a>) is an open-label, multicenter Phase 1\/2 study, designed to evaluate the safety and efficacy of rinatabart sesutecan (Rina-S) Q3W at various doses in solid tumors that are known to express FR\u03b1. The study consists of multiple parts including Part A dose escalation; Part B tumor-specific monotherapy dose-expansion cohorts; Part C platinum-resistant ovarian cancer (PROC) cohort; Part D combination therapy cohorts; Part F a monotherapy endometrial cancer (EC) cohort.<\/p>\nAbout Endometrial Cancer
\n
<\/b>Endometrial cancer (EC) starts in the lining of the uterus, known as the endometriumi <\/sup>and ranks as the second most prevalent gynecologic cancer globally, with increasing incidence and mortality ratesii,iii<\/sup>.Patients with advanced or recurrent EC have a relatively poor prognosis and treatment options are limited for those patients who have progressed following treatment with chemotherapy and immune checkpoint inhibitor. FR\u03b1 is overexpressed on multiple tumors, including EC, making it a promising therapeutic target. Anti-tumor activity with Rina-S was observed across a broad range of FR\u03b1 expression, and there are currently no approved FR\u03b1-directed therapies approved for the treatment of endometrial cancer.<\/p>\nAbout Rinatabart Sesutecan (Rina-S; GEN1184)
\n
<\/b>Rinatabart sesutecan (Rina-S; GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at folate receptor \u03b1 (FR\u03b1), a novel hydrophilic protease-cleavable linker, and exatecan, a topoisomerase I inhibitor payload. The clinical trial program for Rina-S continues to expand including ovarian, endometrial and other cancers of unmet need.<\/p>\n\nThe safety and efficacy of rinatabart sesutecan has not been established. Please visit www.clinicaltrials.gov<\/a> for more information.<\/p>\n
About Genmab
\n
<\/b>Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab\u2019s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines\u00ae<\/sup>.<\/p>\n\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n
This Media Release contains forward looking statements. The words \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend\u201d and \u201cplan\u201d and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab\u2019s most recent financial reports, which are available on <\/i>www.genmab.com<\/i><\/a>and the risk factors included in Genmab\u2019s most recent Annual Report on Form 20-F and other filings <\/i>with the U.S. Securities and Exchange Commission (SEC), which are available at <\/i>www.sec.gov<\/i><\/a>. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.<\/i><\/p>\n
Genmab A\/S and\/or its subsidiaries own the following trademarks: Genmab\u00ae<\/sup>; the Y-shaped Genmab logo\u00ae<\/sup>; Genmab in combination with the Y-shaped Genmab logo\u00ae<\/sup>; HuMax\u00ae<\/sup>; DuoBody\u00ae<\/sup>; HexaBody\u00ae<\/sup>; DuoHexaBody\u00ae<\/sup>, HexElect\u00ae<\/sup>, KYSO\u00ae <\/sup>and RAINFOL\u2122; Rina-S is a trademark of ProfoundBio, US, Co. and Genmab (Suzhou) Co., Ltd.<\/i><\/p>\n
i<\/sup> Mayo Clinic. Endometrial Cancer. https:\/\/www.mayoclinic.org\/diseases-conditions\/endometrial-cancer\/symptoms-causes\/syc-20352461<\/a>.
\n
ii<\/sup> Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: Cancer today (version 1.1). International Agency for Research on Cancer. 05\/28\/2024 (https:\/\/gco.iarc.who.int\/today<\/a>).
\n
iii<\/sup> Concin N, Matias-Guiu X, Vergote I, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021;31(1):12-39. (In eng). DOI: 10.1136\/ijgc-2020-002230.<\/p>\n<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251016413497\/en\/<\/a><\/span><\/p>\n
\nDavid Freundel, Senior Director, Global Communications & Corporate Affairs
\n
T: +1 609 613 0504; E: dafr@genmab.com<\/a><\/p>\n\nAndrew Carlsen, Vice President, Head of Investor Relations
\n
T: +45 3377 9558; E: acn@genmab.com<\/a><\/p>\nKEYWORDS:<\/b> Denmark Europe<\/p>\n
INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Biotechnology Other Health Health Pharmaceutical Other Science Science Oncology<\/p>\n
- A Phase 3 trial in endometrial cancer is underway<\/strong><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251016413497\/en\/2612168\/3\/Genmab_Logo_Color_RGB.jpg\"){kind=logo}
<\/td>\n<\/tr>\n